170 related articles for article (PubMed ID: 16896144)
1. Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: eleven United States cases, 1996-2004.
Vellozzi C; Mitchell T; Miller E; Casey CG; Eidex RB; Hayes EB
Am J Trop Med Hyg; 2006 Aug; 75(2):333-6. PubMed ID: 16896144
[TBL] [Abstract][Full Text] [Related]
2. Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events.
Khromava AY; Eidex RB; Weld LH; Kohl KS; Bradshaw RD; Chen RT; Cetron MS;
Vaccine; 2005 May; 23(25):3256-63. PubMed ID: 15837230
[TBL] [Abstract][Full Text] [Related]
3. Viscerotropic disease following yellow fever vaccination in Peru.
Whittembury A; Ramirez G; Hernández H; Ropero AM; Waterman S; Ticona M; Brinton M; Uchuya J; Gershman M; Toledo W; Staples E; Campos C; Martínez M; Chang GJ; Cabezas C; Lanciotti R; Zaki S; Montgomery JM; Monath T; Hayes E
Vaccine; 2009 Oct; 27(43):5974-81. PubMed ID: 19679215
[TBL] [Abstract][Full Text] [Related]
4. Adverse events associated with 17D-derived yellow fever vaccination--United States, 2001-2002.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2002 Nov; 51(44):989-93. PubMed ID: 12455906
[TBL] [Abstract][Full Text] [Related]
5. Immune response during adverse events after 17D-derived yellow fever vaccination in Europe.
Bae HG; Domingo C; Tenorio A; de Ory F; Muñoz J; Weber P; Teuwen DE; Niedrig M
J Infect Dis; 2008 Jun; 197(11):1577-84. PubMed ID: 18419548
[TBL] [Abstract][Full Text] [Related]
6. Yellow fever vaccine-associated viscerotropic disease and death in Spain.
Doblas A; Domingo C; Bae HG; Bohórquez CL; de Ory F; Niedrig M; Mora D; Carrasco FJ; Tenorio A
J Clin Virol; 2006 Jun; 36(2):156-8. PubMed ID: 16597510
[TBL] [Abstract][Full Text] [Related]
7. Yellow fever-associated viscerotropic disease in Barcelona, Spain.
Muñoz J; Vilella A; Domingo C; Nicolas JM; de Ory F; Corachan M; Tenorio A; Gascon J
J Travel Med; 2008; 15(3):202-5. PubMed ID: 18494699
[TBL] [Abstract][Full Text] [Related]
8. Acute viscerotropic disease following vaccination against yellow fever.
Hayes EB
Trans R Soc Trop Med Hyg; 2007 Oct; 101(10):967-71. PubMed ID: 17669451
[TBL] [Abstract][Full Text] [Related]
9. Risk groups for yellow fever vaccine-associated viscerotropic disease (YEL-AVD).
Seligman SJ
Vaccine; 2014 Oct; 32(44):5769-75. PubMed ID: 25192973
[TBL] [Abstract][Full Text] [Related]
10. Yellow fever vaccine-associated neurologic and viscerotropic disease: a 10-year case series of the French National Reference Center for Arboviruses with clinical and immunological insights.
Le Hir A; Durand GA; Boucraut J; Garnier A; Mura M; Diamantis S; Carles M; Durand C; Schweitzer C; Audouard C; Decroix V; Boyez R; Van Dendriessche A; Leclancher A; Kaphan E; Barbat du Closel L; Verdon R; du Cheyron D; Vabret A; Vergnon D; Grard G; Charrel R; de Lamballerie X; Eldin C
J Travel Med; 2024 Mar; 31(2):. PubMed ID: 38123499
[TBL] [Abstract][Full Text] [Related]
11. Risk of yellow fever vaccine-associated viscerotropic disease among the elderly: a systematic review.
Rafferty E; Duclos P; Yactayo S; Schuster M
Vaccine; 2013 Dec; 31(49):5798-805. PubMed ID: 24079979
[TBL] [Abstract][Full Text] [Related]
12. First case of yellow fever vaccine-associated viscerotropic disease (YEL-AVD) in Hong Kong.
Leung WS; Chan MC; Chik SH; Tsang TY
J Travel Med; 2016 Apr; 23(4):. PubMed ID: 27087559
[TBL] [Abstract][Full Text] [Related]
13. A case suspected for yellow fever vaccine-associated viscerotropic disease in the Netherlands.
van de Pol EM; Gisolf EH; Richter C
J Travel Med; 2014; 21(6):421-4. PubMed ID: 24920138
[TBL] [Abstract][Full Text] [Related]
14. Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases.
McMahon AW; Eidex RB; Marfin AA; Russell M; Sejvar JJ; Markoff L; Hayes EB; Chen RT; Ball R; Braun MM; Cetron M;
Vaccine; 2007 Feb; 25(10):1727-34. PubMed ID: 17240001
[TBL] [Abstract][Full Text] [Related]
15. Rare case of fatal yellow fever vaccine-associated viscerotropic disease.
Gerasimon G; Lowry K
South Med J; 2005 Jun; 98(6):653-6. PubMed ID: 16004173
[TBL] [Abstract][Full Text] [Related]
16. Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: systematic review.
Thomas RE; Lorenzetti DL; Spragins W; Jackson D; Williamson T
Vaccine; 2011 Jun; 29(28):4544-55. PubMed ID: 21549787
[TBL] [Abstract][Full Text] [Related]
17. Yellow fever vaccine usage in the United States and risk of neurotropic and viscerotropic disease: A retrospective cohort study using three healthcare databases.
Ledlie S; Ricci C; Pan C; Rojas A; Khromava A; Li L
Vaccine; 2022 Jan; 40(5):742-751. PubMed ID: 34996642
[TBL] [Abstract][Full Text] [Related]
18. Review of the risks and benefits of yellow fever vaccination including some new analyses.
Monath TP
Expert Rev Vaccines; 2012 Apr; 11(4):427-48. PubMed ID: 22551029
[TBL] [Abstract][Full Text] [Related]
19. Adverse event reports following yellow fever vaccination, 2007-13.
Lindsey NP; Rabe IB; Miller ER; Fischer M; Staples JE
J Travel Med; 2016 May; 23(5):. PubMed ID: 27378369
[TBL] [Abstract][Full Text] [Related]
20. Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010.
Breugelmans JG; Lewis RF; Agbenu E; Veit O; Jackson D; Domingo C; Böthe M; Perea W; Niedrig M; Gessner BD; Yactayo S;
Vaccine; 2013 Apr; 31(14):1819-29. PubMed ID: 23395587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
